Veru's stock price surged over 167% after announcing a clinical supply agreement with Novo Nordisk for a Phase 2b trial. Novo Nordisk will supply Wegovy at no cost for the trial testing enobosarm combined with Wegovy in older adults with obesity. Novo Nordisk also secured first negotiation rights on future commercial opportunities.
Veru Inc. experienced a significant surge in its stock price, jumping over 167% in mid-day trading on Thursday. This surge followed the company's disclosure of a formal clinical supply agreement with Novo Nordisk, filed with the SEC on June 4, 2026. The agreement, signed on June 2, 2026, pertains to Veru's ongoing Phase 2b PLATEAU clinical study, which is evaluating enobosarm in combination with Novo Nordisk's weight-loss drug Wegovy (semaglutide) in older adults with obesity. Under the terms of the deal, Novo Nordisk will supply Wegovy to Veru at no cost for the duration of the trial, providing meaningful cost relief for the small-cap biotech. Additionally, Novo Nordisk has secured first negotiation rights on any future commercial opportunities involving a combination of enobosarm and GLP-1 drugs, which investors interpreted as a strong signal of confidence. Veru's stock moved from a previous close of $2.25 to a session high of $6.02, nearing its 52-week high of $7.40. Trading volume significantly exceeded the average daily turnover, driven by retail and momentum buyers. The PLATEAU trial builds upon earlier data from the Phase 2b QUALITY study, where the enobosarm and semaglutide combination showed greater fat loss and helped prevent weight regain while preserving lean muscle. The broader market was mixed on Thursday, with the S&P 500 and Dow Jones rising while the Nasdaq slipped. Novo Nordisk's stock also saw a modest increase of approximately 4.17% during the session.
This collaboration signals strong potential for Veru's enobosarm drug in combination therapy, attracting significant investor interest and potentially validating a new approach to obesity treatment beyond single-agent GLP-1 therapies.